The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Combination Therapy for Mucormycosis: Why, What, and How?
Open accessAbstract
The high mortality rate of mucormycosis with currently available monotherapy, particularly in hematology patients, has stimulated interest in studying novel combinations of antifungal agents to determine whether superior outcomes might be achieved. Combination lipid polyene-echinocandin therapy is the most promising of such regimens based on safety profile, the availability of parenteral formulations of echinocandins, their synergy in murine models of mucormycosis, and observational clinical data that are concordant. Other options include combination lipid polyene plus deferasirox or posaconazole therapy. Definitive, randomized, placebo-controlled phase III clinical trials are needed to determine whether combination therapy with any of these options is superior to monotherapy. Until such studies are conducted, clinicians will continue to be placed in the unacceptable position of not knowing if and when to administer combination therapy. Such a state of confusion may lead to undertreatment if combination therapy is indeed superior but is not used and, conversely, may lead to unacceptable toxicity and cost to patients if combination therapy is not superior but is used. It is critical that sponsors step forward with funding to conduct these clinical trials to determine whether outcomes from these devastating infections can be improved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Self-citationSpellberg, B., Ibrahim, A. S., Chin-Hong, P. V., Kontoyiannis, D. P., Morris, M. I., Perfect, J. R., Fredricks, D., & Brass, E. P. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr375 · Cited by 308
Self-citationPharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis
Andes, D., Marchillo, K., Conklin, R., Krishna, G., Ezzet, F., Cacciapuoti, A., & Loebenberg, D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.137-142.2004 · Cited by 177
Cited by
Stevens, D. L., Bisno, A. L., Chambers, H. F., Dellinger, E. P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, S. L., Montoya, J. G., & Wade, J. C. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu296 · Cited by 2,780
Sen, M., Honavar, S. G., Bansal, R., Sengupta, S., Rao, R., Kim, U., Sharma, M., Sachdev, M., Grover, A. K., Surve, A., et al. (2021) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1565_21 · Cited by 418
Skiada, A., Lanternier, F., Groll, A. H., Pagano, L., Zimmerli, S., Herbrecht, R., Lortholary, O., Petrikkos, G. L., & Leukemia*, O. B. O. T. T. E. C. O. I. I. (2013) · Haematologica · doi:10.3324/haematol.2012.065110 · Cited by 372
Self-citationAntifungal combinations in Mucorales: A microbiological perspective
Schwarz, P., Cornely, O. A., & Dannaoui, E. (2019) · Mycoses · doi:10.1111/myc.12909 · Cited by 43
Metadata
- Authors
- Spellberg, B., Ibrahim, A., Roilides, E., Lewis, R. E., Lortholary, O., Petrikkos, G., Kontoyiannis, D. P., & Walsh, T. J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-02-01
- Volume
- 54
- Issue
- suppl_1
- Pages
- S73-S78
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2114432945
- Cited by
- 171
- References
- 3
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination Therapy for Mucormycosis: Why, What, and How? https://app.cochat.ai/papers/10.1093/cid/cir885
- The paper
- Spellberg, B., Ibrahim, A., Roilides, E., Lewis, R. E., Lortholary, O., Petrikkos, G., Kontoyiannis, D. P., & Walsh, T. J. (2012). Combination Therapy for Mucormycosis: Why, What, and How? Clinical Infectious Diseases. https://doi.org/10.1093/cid/cir885
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.